Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company whose news flow is closely tied to the development of its two lead small molecule drug candidates, enobosarm and sabizabulin. Company press releases emphasize cardiometabolic and inflammatory diseases, with a particular focus on obesity, chronic weight management, and inflammation in atherosclerotic cardiovascular disease.
Much of Veru’s recent news has centered on enobosarm, a selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP-1 receptor agonist (GLP-1 RA) drugs more tissue selective for fat loss while preserving lean mass and physical function. Updates include topline efficacy and safety data from the Phase 2b QUALITY study and its Maintenance Extension, which evaluated enobosarm in older patients receiving semaglutide for weight reduction. The company has reported that enobosarm plus semaglutide preserved lean mass, increased fat loss, and reduced declines in stair climb power compared to placebo plus semaglutide, as well as reduced weight and fat regain after semaglutide discontinuation.
Investors following VERU news will also see announcements about regulatory interactions and trial design. Veru has disclosed a successful FDA meeting that, according to the company, provided regulatory clarity for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, including guidance that incremental weight loss can serve as an acceptable primary endpoint and confirmation of the 3 mg dose for future development. News releases describe the planned Phase 2b PLATEAU study, designed to evaluate enobosarm 3 mg in patients with obesity initiating GLP-1 RA treatment, with endpoints focused on total body weight, body composition, and physical function.
Additional VERU headlines cover capital markets activity and corporate actions, such as an underwritten public offering to fund enobosarm development, a 1-for-10 reverse stock split, and Nasdaq notifications regarding minimum bid price compliance. Conference presentations at scientific meetings, collaborations on a modified release enobosarm formulation using Laxxon Medical’s SPID-Technology, and periodic financial results also feature prominently in the company’s news stream.
For investors and observers, the Veru news page provides a consolidated view of clinical trial milestones, FDA-related updates, financing transactions, and scientific presentations that shape the outlook for VERU’s cardiometabolic and inflammatory disease programs.
Veru (NASDAQ: VERU) reported Q1 fiscal 2026 results and clinical updates. Cash was $33.0M as of Dec 31, 2025. Operating loss improved to $5.4M and net loss was $5.3M ($0.26/share).
Veru plans a ~200-patient Phase 2b PLATEAU trial of enobosarm plus semaglutide starting Q1 2026 with an interim analysis planned Q1 2027; FDA provided regulatory pathways including a 5% placebo-corrected weight-loss benchmark or alternative functional/BMD benefits.
Veru (NASDAQ: VERU) will report fiscal 2026 first quarter results and host a conference call and audio webcast on Wednesday, February 11, 2026 at 8:00 a.m. ET.
The webcast is accessible via the company's website; teleconference dial‑in numbers and replay details are provided. An archived webcast will be available for approximately three months; a telephonic replay will be available for one week.
Veru (NASDAQ: VERU) reported fiscal 2025 results and clinical progress for enobosarm in obesity on Dec 17, 2025. Key clinical highlights include FDA regulatory clarity that a ≥5% placebo‑corrected incremental weight loss at 52 weeks or smaller weight difference with clinically meaningful physical function benefit may support approval. Phase 2b PLATEAU (enobosarm 3 mg + GLP‑1 RA) is planned to start Q1 2026 with interim analysis expected Q1 2027. Fiscal 2025 results: cash $15.8M (9/30/25), R&D $15.6M, operating loss $24.8M; company completed a post‑period public offering for ~$23.4M net proceeds.
Veru (NASDAQ: VERU) will report fiscal year 2025 financial results and provide a business update on Wednesday, December 17, 2025 at 8:00 a.m. ET. The company will host a conference call and live audio webcast accessible from the Home and Investors pages at www.verupharma.com. A replay of the webcast will be archived on the company website for approximately three months. A telephonic replay will be available from about 12:00 p.m. ET for one week by dialing the provided replay numbers with passcode 2225332.
Veru (NASDAQ: VERU) will present multiple times at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and the SCWD Regulatory and Clinical Trials Update Workshop in Rome, Italy on December 11–13, 2025. Mitchell Steiner, Veru’s Chairman, President & CEO, is the company presenter.
Key sessions include: a workshop discussion on treatment approaches and regulatory issues for muscle wasting during obesity therapy (Dec 11, 10:15–11:15 CET and 11:15–11:55 CET), a presentation on weight loss drugs and cardiovascular health (Dec 12, 16:30–16:45 CET), and a roundtable on novel sarcopenia strategies while treating obesity including an update on Enobosarm (Dec 13, 10:00–10:15 CET). Locations: A. Roma Lifestyle Hotel, Hall A.
Veru (NASDAQ: VERU) will present two abstracts at ObesityWeek 2025 in Atlanta, November 4-7, 2025.
Poster: "Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide" presented by Steven B. Heymsfield, M.D., on Tuesday, November 4, 2025, 7:30 pm–8:30 pm ET in Exhibit Hall A1. Oral: "Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function" presented by Mitchell Steiner, M.D., on Friday, November 7, 2025, 8:00 am–8:15 am ET in GWCC Building A: A411-A412.
Additional meeting details are available at https://obesityweek.org/.
Veru (NASDAQ: VERU)Oct 30, 2025 consisting of 1,400,000 common shares, pre-funded warrants for up to 7,000,000 shares, and accompanying Series A and Series B warrants to purchase up to 8,400,000 shares each.
The combined public offering price per share with warrants is $3.00 (pre-funded combined price $2.999). Gross proceeds are expected to be approximately $25.2 million at closing (on or about Oct 31, 2025); cash exercise of all warrants would yield an additional $50.4 million. Net proceeds are planned to fund development of enobosarm, primarily the Phase 2b PLATEAU clinical study, and for working capital and general corporate purposes.
Veru (NASDAQ: VERU) announced on October 29, 2025 that it has commenced an underwritten public offering of shares of common stock (or pre-funded warrants) together with accompanying Series A and Series B warrants. The offering is subject to market and other conditions and may not be completed.
Use of proceeds is stated as funding development of enobosarm with a primary focus on the Phase 2b PLATEAU clinical study, plus working capital, existing vendor obligations, and potential development partner activities. Canaccord Genuity and Oppenheimer are joint book-running managers. The securities will be offered under a shelf registration statement on Form S-3 declared effective April 14, 2023, with a preliminary prospectus supplement to be filed with the SEC.
Veru (NASDAQ: VERU) announced a successful FDA meeting regarding enobosarm, their muscle preservation drug candidate for obesity treatment. The FDA provided key regulatory clarity, accepting incremental weight loss as a primary endpoint when enobosarm is combined with GLP-1 RA treatments. The agency confirmed 3mg as an acceptable dosage and encouraged expanding the program to younger obesity patients.
Based on their positive Phase 2 QUALITY study results, Veru plans to initiate a Phase 2b PLATEAU clinical study in Q1 2026. The study will evaluate enobosarm 3mg in approximately 180 patients, both older (≥65) and younger (<65), who are starting tirzepatide treatment. The trial aims to demonstrate enobosarm's ability to preserve muscle mass while promoting additional fat loss, particularly in patients reaching the GLP-1 RA weight loss plateau.
Veru Inc. (NASDAQ: VERU) reported positive results from its Phase 2b QUALITY study evaluating enobosarm in combination with semaglutide for weight loss management. The study showed that enobosarm 3mg + semaglutide achieved 100% preservation of lean mass compared to placebo + semaglutide at 16 weeks (p<0.001). The combination resulted in 100% fat mass loss versus 66% for placebo + semaglutide.
In the Maintenance Extension study, enobosarm 3mg reduced body weight regain by 46% after semaglutide discontinuation. The company also announced a novel modified release oral enobosarm formulation with patent protection through 2046. For Q3 2025, Veru reported reduced operating losses of $7.5 million compared to $10.5 million year-over-year, with cash reserves of $15.0 million as of June 30, 2025.